Inactive Instrument

Dignitana AB Share Price Swiss Exchange

Equities

DIGN

SE0002108001

Medical Equipment, Supplies & Distribution

End-of-day quote Swiss Exchange
- SEK - Intraday chart for Dignitana AB

Financials

Sales 2023 86.06M 8.18M 642M Sales 2024 * 120M 11.38M 893M Capitalization 145M 13.74M 1.08B
Net income 2023 -17M -1.62M -127M Net income 2024 * 3M 285K 22.37M EV / Sales 2023 1.94 x
Net Debt 2023 13.08M 1.24M 97.5M Net Debt 2024 * 3.2M 304K 23.86M EV / Sales 2024 * 1.23 x
P/E ratio 2023
-8.72 x
P/E ratio 2024 *
-
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 68.27%
More Fundamentals * Assessed data
Managers TitleAgeSince
Director of Finance/CFO 53 30/06/22
Chairman 64 31/12/19
Chief Tech/Sci/R&D Officer 46 28/02/22
Members of the board TitleAgeSince
Chairman 64 31/12/19
Director/Board Member 61 31/12/19
Director/Board Member 51 31/12/20
More insiders
Dignitana AB is a Sweden-based medical technology company. It develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The Company focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold cap, which when put on the patient’s head, lowers the temperature of the scalp. The low temperature reduces perfusion, delivery of blood and metabolism. The reduced blood flow results in a smaller amount of chemotherapy available for uptake in the cells, while the decreased temperature results in less absorption and reduced effects of chemotherapy. These factors together reduce the risk of hair loss. The DigniCap scalp cooling system is patented in Europe, Japan and the United States. It has a subsidiary BrainCool AB, which focuses on producing different models of brain cooling for stroke and cardiac arrest patients.
Calendar
More about the company